Defibrotide

Introduction: What is Defibrotide?

Defibrotide is a medication used to treat severe hepatic sinusoidal obstruction syndrome (SOS), formerly known as hepatic veno-occlusive disease (VOD), particularly when associated with renal or pulmonary dysfunction following hematopoietic stem cell transplantation (HSCT). It is derived from a mixture of single-stranded deoxyribonucleic acid (DNA) fragments and exerts endothelial-protective, profibrinolytic, and anti-inflammatory effects, helping restore normal blood flow in the hepatic microvasculature without causing systemic anticoagulation.

Uses of Defibrotide

Defibrotide is approved for the treatment of severe hepatic sinusoidal obstruction syndrome (SOS) with renal and/or pulmonary dysfunction following HSCT in both adults and children. Although investigational research is ongoing in other vascular and thrombotic conditions, its only established and approved indication remains post-transplant SOS.

How It Works

Defibrotide works by protecting and stabilizing endothelial cells lining the blood vessels of the liver. It enhances local fibrinolysis, reduces endothelial activation, and improves microcirculatory blood flow without significantly affecting systemic coagulation parameters. In simple terms, Defibrotide helps the liver?s smallest blood vessels recover from injury and inflammation, allowing blood to flow more freely and reducing further organ damage.

Dosage and Administration

The recommended dose for both adults and children is 25 mg/kg/day, administered as 6.25 mg/kg every 6 hours via intravenous infusion over 2 hours. Treatment should continue for a minimum of 21 days and until resolution of SOS signs and symptoms. Defibrotide should be administered under specialist supervision in a hospital setting.

Side Effects of Defibrotide

Like all medications, Defibrotide can cause side effects.

Common adverse effects

• Diarrhea
• Nausea and vomiting
• Hypotension
• Fever
• Epistaxis

Serious adverse effects

• Bleeding (gastrointestinal, pulmonary, intracranial)
• Hypersensitivity reactions
• Hemorrhagic complications, particularly in patients on concomitant anticoagulants

Because Defibrotide promotes fibrinolysis, bleeding is the most clinically significant risk and requires close monitoring.

Drug Interactions

Defibrotide may interact with other medications, which can affect its efficacy or increase the risk of side effects. Major drug interactions include:

• Anticoagulants (blood thinners) like warfarin or heparin, which may increase the risk of bleeding.
• Other medications that affect liver function or blood clotting.

It is crucial for patients to inform their healthcare provider about all medications they are taking, including over-the-counter drugs and supplements.

Benefits of Defibrotide

Defibrotide offers several clinical advantages, including:

• Targeted treatment for HVOD, which can significantly improve patient outcomes.
• Reduction in the severity of liver damage and associated complications.
• Potential to enhance recovery in patients undergoing stem cell transplantation.

These benefits make Defibrotide a valuable option in managing a challenging condition like HVOD.

Contraindications of Defibrotide

Defibrotide is contraindicated in:

• Patients with active, uncontrolled bleeding
• Patients receiving systemic anticoagulant or fibrinolytic therapy
• Known hypersensitivity to Defibrotide or its components
• Pregnancy: Use only if potential benefit outweighs risk; not absolutely contraindicated.

Precautions and Warnings

Before starting treatment with Defibrotide, patients should undergo specific lab tests to assess liver function and overall health. It is important to monitor for signs of bleeding and liver function during treatment. Patients should also inform their healthcare provider about any preexisting conditions or medications they are taking to avoid potential complications.

FAQs

1. What is Defibrotide used for? Defibrotide is used to treat hepatic venoocclusive disease (HVOD) in patients who have undergone stem cell transplantation.
2. How is Defibrotide administered? Defibrotide is given as an intravenous (IV) infusion, typically four times a day.
3. What are the common side effects of Defibrotide? Common side effects include diarrhea, nausea, vomiting, fever, and rash.
4. Can Defibrotide be used in children? Yes, Defibrotide can be used in children, but the dosage may vary based on weight and age.
5. Are there any serious side effects? Yes, serious side effects can include severe bleeding, allergic reactions, and liver function abnormalities.
6. What should I do if I miss a dose? If you miss a dose, contact your healthcare provider for guidance on what to do next.
7. Can I take other medications with Defibrotide? Inform your healthcare provider about all medications you are taking, as some may interact with Defibrotide.
8. Is Defibrotide safe during pregnancy? The safety of Defibrotide during pregnancy has not been established, so it should be avoided unless prescribed by a doctor.
9. How long is the treatment with Defibrotide? Treatment typically lasts for at least 21 days or until the patient's condition improves.
10. Where can I find more information about Defibrotide? For more information, consult your healthcare provider or refer to the medication guide provided with your prescription.

Brand Names

Defibrotide is marketed under the brand name Defitelio?. It is essential to use the medication as prescribed and to be aware of its brand name when discussing treatment options with healthcare providers.

Conclusion

Defibrotide is a specialized endothelial-protective therapy for the management of severe hepatic sinusoidal obstruction syndrome following stem cell transplantation. When used appropriately, it improves survival by restoring hepatic microvascular flow and reducing organ failure. Due to the risk of bleeding, its use requires careful patient selection, hospital-based administration, and close monitoring under specialist care.